Neoral Articles
Roche's CellCept gets expanded label in USA
10 August 2000
Stock Commentary New York
25 May 2000
Correction: Abbott's Gengraf
25 May 2000
Fujisawa fiscal 1999 turnover driven by Prograf
24 May 2000
Novartis sees launch of cancer drug by 2001
18 April 2000
Allergan launches Alocril in USA
2 March 2000
Novartis says 25% chance Zelmac NDA will not be accepted
22 February 2000
Canada's Isotechnika to test transplant drug
10 February 2000
Yoshitomi rises on organ rejection drug
21 December 1999
Novartis loses battles over Neoral labeling and rapamycin patent
9 December 1999
Novartis to increase investment in Spain
26 November 1999
Fujisawa earnings driven by Prograf; pipeline looking healthy
15 November 1999
AHP weathers the storm with first Rapamune approval
17 September 1999
FDA says Allergan's Restasis is approvable
26 August 1999
Abbot completes $14 equity investment in SangStat
12 August 1999
Stock Commentary Tokyo
29 July 1999
Stock Commentary New York
29 July 1999
FDA panel backs Wyeth's Rapamune
28 July 1999
Allergan's Restasis, Phase III data
23 July 1999
Stock Commentary Tokyo
1 July 1999
Abbott to copromote SangStat's cyclosporine
11 May 1999
-SangStat launches SangCya Oral Solution in UK
15 April 1999
Direct cancer link to cyclosporine?
18 February 1999
- Novartis files two separate lawsuits
16 February 1999
Priority Review for Rapamune in USA
2 February 1999
Novartis 1998 sales down on forecasts
21 January 1999
Basiliximab Launched In The UK
8 December 1998
SangStat Gets US Approval For Generic Cyclosporine
3 November 1998
EU Approval For Novartis' Simulect
16 October 1998
Quadrant Drops Lead Compound
8 October 1998
Novartis Restructures After Disappointing First Half
1 September 1998
AHP's Rapamune Improves 6-Month Graft Survival
16 July 1998
Gensia Buys Remaining Stake In Diaspa
2 July 1998
Euro CPMP April Plenary Meeting
18 June 1998
Modest Sales Growth At Novartis Worries Market
17 June 1998
Novartis Granted First Approval For Simulect
16 April 1998
First Operational Year Strong At Novartis
19 March 1998
France's Fournier Gets Ready To Blossom
12 March 1998
SangStat's Ciclosporin Nearing US Market
13 February 1998
Drug Delivery Sales "To Grow 15% A Year To 2005"
4 February 1998
SangStat To Go For New Thymoglobulin Indication
15 January 1998
SangStat Ciclosporin Takes On Sandimmun
6 November 1997
Novartis' Nine-Month Drug Sales Climb 26%
30 October 1997
US 3rd Qtr Corporate Results Round-Up
30 October 1997
Phase III Results With Novartis' Basiliximab
29 October 1997
Roche's Zenapax Gets Backing Of FDA Panel
23 October 1997
Phase III Results With IMTIX' Antirejection Antibody
23 October 1997
UK Industry Code Of Practice Report
1 September 1997
Neoral Launched For Arthritis In USA
31 July 1997
Strong Pharmaceutical Growth Drives Novartis
24 July 1997
Sangstat's Marketing Strategy For Ciclosporin
17 June 1997
Roche And PDL Report Positive Data With Zenapax
19 May 1997
Health Care Fuels Strong 1997 Start For Novartis
21 April 1997
1996 A Demanding Year For Novartis
19 March 1997
Neoral Backed For Severe Arthritis By FDA Panel
10 February 1997
FDA "Will Review" SangStat's AADA For Ciclosporin
3 February 1997
Sales Advance 8% In 1996 At Novartis
3 February 1997
SangStat's Ciclosporin "Bioequivalent" To Neoral
13 January 1997
Novartis Partners 9 Months Figures Disappoint
28 October 1996
....Nutrition Downturn And Currency Holds Sandoz Back
29 April 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
EMEA Approves Roche's CellCept
26 February 1996
Sales Growth For Sandoz In 1995
22 January 1996
SangStat ciclosporin trials
13 November 1995
Sandoz 9 Months Sales up 6%
6 November 1995
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
EUROPEAN STOCK COMMENT
18 September 1995
US Plan For Literature On Unapproved Uses Of Drug
11 September 1995
Sandoz' Neoral Free To South African Children
14 August 1995
Sandoz's Neoral approved in the USA
31 July 1995
Sandoz Half-Year Sales Up 6%, But Pharma Down 2%
24 July 1995
Prograf Linked To Cardiotoxicity?
17 April 1995
Neoral Launched In UK
17 April 1995
FDA Panel Backs Cellcept For Acute Rejection
10 April 1995
Roussel-Uclaf Details Group Pipeline Plans
10 April 1995
Cross-Species Transplants Nearing Reality?
3 April 1995
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
